The role of type 1 interferon in systemic sclerosis

Frontiers in Immunology

Volumn 4, Issue SEP, 2013, Pages

  Wu, Minghua ^a   Assassi, Shervin ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

IFN inducible cytokines and chemokines; Innate immunity; Interferon regulatory factor; Systemic sclerosis; Type 1 IFN

Indexed keywords

EID: 84886081492     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00266     Document Type: Review

References (102)

1. Sapadin AN, Esser AC, Fleischmajer R. Immunopathogenesis of scleroderma-evolving concepts. Mt Sinai J Med (2001) 68(4-5):233-42.
2. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum (2003) 48(8):2246-55. doi:10.1002/art.11073.
3. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) (2012) 51(6):1017-26. doi:10.1093/rheumatology/ker269.
4. Platanias LC. Interferons: laboratory to clinic investigations. Curr Opin Oncol (1995) 7(6):560-5. doi:10.1097/00001622-199511000-00015.
5. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem (1998) 67:227-64. doi:10.1146/annurev.biochem.67.1.227.
6. Paucker K, Cantell K, Henle W. Quantitative studies on viral interference in suspended L cells. III. Effect of interfering viruses and interferon on the growth rate of cells. Virology (1962) 17:324-34. doi:10.1016/0042-6822(62)90123-X.
7. Kraling BM, Maul GG, Jimenez SA. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology (1995) 63(1):48-56. doi:10.1159/000163933.
8. Ishikawa O, Ishikawa H. Macrophage infiltration in the skin of patients with systemic sclerosis. J Rheumatol (1992) 19(8):1202-6.
9. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol (1992) 166(3):255-63. doi:10.1002/path.1711660307.
10. Roumm AD, Whiteside TL, Medsger TA Jr., Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum (1984) 27(6):645-53. doi:10.1002/art.1780270607.
11. Fiocco U, Rosada M, Cozzi L, Ortolani C, De Silvestro G, Ruffatti A, et al. Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity. Ann Rheum Dis (1993) 52(4):272-7. doi:10.1136/ard.52.4.272.
12. Higashi-Kuwata N, Makino T, Inoue Y, Takeya M, Ihn H. Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma. Exp Dermatol (2009) 18(8):727-9. doi:10.1111/j.1600-0625.2008.00828.x.
13. Andrews BS, Friou GJ, Berman MA, Sandborg CI, Mirick GR, Cesario TC. Changes in circulating monocytes in patients with progressive systemic sclerosis. J Rheumatol (1987) 14(5):930-5.
14. Anders HJ, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int (2011) 80(9):915-25. doi:10.1038/ki.2011.217.
15. Gordon S. Alternative activation of macrophages. Nat Rev Immunol (2003) 3(1):23-35. doi:10.1038/nri978.
16. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol (2006) 177(10):7303-11.
17. Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther (2010) 12(4):R128. doi:10.1186/ar3066.
18. Nakayama W, Jinnin M, Makino K, Kajihara I, Makino T, Fukushima S, et al. Serum levels of soluble CD163 in patients with systemic sclerosis. Rheumatol Int (2012) 32(2):403-7. doi:10.1007/s00296-010-1691-z.
19. Yukawa S, Yamaoka K, Sawamukai N, Shimajiri S, Kubo S, Miyagawa I, et al. Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis. Mod Rheumatol (2012):doi:10.1007/s10165-012-0813-8.
20. Mason GI, Hamburger J, Matthews JB. Mast cells, extracellular matrix components, TGFbeta isoforms and TGFbeta receptor expression in labial salivary glands in systemic sclerosis. Ann Rheum Dis (2000) 59(3):183-9. doi:10.1136/ard.59.3.183.
21. Hugle T, Hogan V, White KE, van Laar JM. Mast cells are a source of transforming growth factor beta in systemic sclerosis. Arthritis Rheum (2011) 63(3):795-9. doi:10.1002/art.30190.
22. de Paulis PA, Valentini G, Spadaro G, Lupoli S, Tirri G, Marone G. Human basophil releasability. VIII. Increased basophil releasability in patients with scleroderma. Arthritis Rheum (1991) 34(10):1289-96. doi:10.1002/art.1780341013.
23. Riccieri V, Parisi G, Spadaro A, Scrivo R, Barone F, Moretti T, et al. Reduced circulating natural killer T cells and gamma/delta T cells in patients with systemic sclerosis. J Rheumatol (2005) 32(2):283-6.
24. Rueda B, Broen J, Simeon C, Hesselstrand R, Diaz B, Suarez H, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet (2009) 18(11):2071-7. doi:10.1093/hmg/ddp119.
25. Gourh P, Agarwal SK, Divecha D, Assassi S, Paz G, Arora-Singh RK, et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum (2009) 60(12):3794-806. doi:10.1002/art.24958.
26. Radstake TR, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, Palomino-Morales R, et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet (2010) 42(5):426-9. doi:10.1038/ng.565.
27. Dawidowicz K, Dieude P, Avouac J, WipffJ, Hachulla E, Diot E, et al. Association study of B-cell marker gene polymorphisms in European caucasian patients with systemic sclerosis. Clin Exp Rheumatol (2011) 29(5):839-42.
28. Coustet B, Dieude P, Guedj M, Bouaziz M, Avouac J, Ruiz B, et al. C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: results from a large French cohort and meta-analysis. Arthritis Rheum (2011) 63(7):2091-6. doi:10.1002/art.30379.
29. Gourh P, Agarwal SK, Martin E, Divecha D, Rueda B, Bunting H, et al. Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. J Autoimmun (2010) 34(2):155-62. doi:10.1016/j.jaut.2009.08.014.
30. Ito I, Kawaguchi Y, Kawasaki A, Hasegawa M, Ohashi J, Kawamoto M, et al. Association of the FAM167A-BLK region with systemic sclerosis. Arthritis Rheum (2010) 62(3):890-5. doi:10.1002/art.27303.
31. Dieude P, WipffJ, Guedj M, Ruiz B, Melchers I, Hachulla E, et al. BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4. Arthritis Rheum (2009) 60(11):3447-54. doi:10.1002/art.24885.
32. Rueda B, Gourh P, Broen J, Agarwal SK, Simeon C, Ortego-Centeno N, et al. BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in caucasians. Ann Rheum Dis (2010) 69(4):700-5. doi:10.1136/ard.2009.118174.
33. Sharif R, Mayes MD, Tan FK, Gorlova OY, Hummers LK, Shah AA, et al. IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. Ann Rheum Dis (2012) 71(7):1197-202. doi:10.1136/annrheumdis-2011-200901.
34. Dieude P, Guedj M, WipffJ, Avouac J, Fajardy I, Diot E, et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum (2009) 60(1):225-33. doi:10.1002/art.24183.
35. Carmona FD, Gutala R, Simeon CP, Carreira P, Ortego-Centeno N, Vicente-Rabaneda E, et al. Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis. Ann Rheum Dis (2012) 71(1):114-9. doi:10.1136/annrheumdis-2011-200275.
36. Gorlova O, Martin JE, Rueda B, Koeleman BP, Ying J, Teruel M, et al. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet (2011) 7(7):e1002178. doi:10.1371/journal.pgen.1002178.
37. Terao C, Ohmura K, Kawaguchi Y, Nishimoto T, Kawasaki A, Takehara K, et al. PLD4 as a novel susceptibility gene for systemic sclerosis in a Japanese population. Arthritis Rheum (2013) 65(2):472-80. doi:10.1002/art.37777.
38. Martin JE, Broen JC, Carmona FD, Teruel M, Simeon CP, Vonk MC, et al. Identification of CSK as a systemic sclerosis genetic risk factor through genome wide association study follow-up. Hum Mol Genet (2012) 21(12):2825-35. doi:10.1093/hmg/dds099.
39. Farina GA, York MR, Di MM, Collins CA, Meller S, Homey B, et al. Poly(I:C) drives type I IFN-and TGFbeta-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. J Invest Dermatol (2010) 130(11):2583-93. doi:10.1038/jid.2010.200.
40. Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) (2006) 45(6):694-702. doi:10.1093/rheumatology/kei244.
41. York MR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, Lafyatis R. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum (2007) 56(3):1010-20. doi:10.1002/art.22382.
42. Duan H, Fleming J, Pritchard DK, Amon LM, Xue J, Arnett HA, et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum (2008) 58(5):1465-74. doi:10.1002/art.23451.
43. Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis (2011) 70(11):2029-36. doi:10.1136/ard.2011.150326.
44. Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis (2011) 70(11):1905-13. doi:10.1136/ard.2010.144485.
45. Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum (2013) 65(4):1011-21. doi:10.1002/art.37824.
46. Assassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, McNearney TA, et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum (2010) 62(2):589-98. doi:10.1002/art.27224.
47. Eloranta ML, Franck-Larsson K, Lovgren T, Kalamajski S, Ronnblom A, Rubin K, et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis (2010) 69(7):1396-402. doi:10.1136/ard.2009.121400.
48. Kim D, Peck A, Santer D, Patole P, Schwartz SM, Molitor JA, et al. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum (2008) 58(7):2163-73. doi:10.1002/art.23486.
49. Solans R, Bosch JA, Esteban I, Vilardell M. Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis. Clin Exp Rheumatol (2004) 22(5):625-8.
50. Black CM, Silman AJ, Herrick AI, Denton CP, Wilson H, Newman J, et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (1999) 42(2):299-305. doi:10.1002/1529-0131(199902)42:2<299::AID-ANR12>3.0.CO;2-R.
51. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell (2006) 124(4):783-801. doi:10.1016/j.cell.2006.02.015.
52. Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum (2006) 54(6):1906-16. doi:10.1002/art.21890.
53. Van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis (2007) 66(8):1008-14. doi:10.1136/ard.2006.063412.
54. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol (2010) 11(5):373-84. doi:10.1038/ni.1863.
55. Bhattacharyya S, Kelley K, Melichian DS, Tamaki Z, Fang F, Su Y, et al. Toll-like receptor 4 signaling augments transforming growth factor-beta responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol (2013) 182(1):192-205. doi:10.1016/j.ajpath.2012.09.007.
56. Agarwal SK, Wu M, Livingston CK, Parks DH, Mayes MD, Arnett FC, et al. Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts. Arthritis Res Ther (2011) 13(1):R3. doi:10.1186/ar3221.
57. Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol (2008) 26:535-84. doi:10.1146/annurev.immunol.26.021607.090400.
58. Mamane Y, Heylbroeck C, Genin P, Algarte M, Servant MJ, LePage C, et al. Interferon regulatory factors: the next generation. Gene (1999) 237(1):1-14. doi:10.1016/S0378-1119(99)00262-0.
59. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol (2001) 19:623-55. doi:10.1146/annurev.immunol.19.1.623.
60. Platanias LC. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 5(5):375-86. doi:10.1038/nri1604.
61. Decker T, Muller M, Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol (2005) 5(9):675-87. doi:10.1038/nri1684.
62. Barnes BJ, Richards J, Mancl M, Hanash S, Beretta L, Pitha PM. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J Biol Chem (2004) 279(43):45194-207. doi:10.1074/jbc. M400726200.
63. Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res (2003) 63(19):6424-31.
64. Barnes BJ, Moore PA, Pitha PM. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem (2001) 276(26):23382-90. doi:10.1074/jbc. M101216200.
65. Honda K, Taniguchi T. IRFs: master regulators of signalling by toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol (2006) 6(9):644-58. doi:10.1038/nri1900.
66. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, et al. Integral role of IRF-5 in the gene induction programme activated by toll-like receptors. Nature (2005) 434(7030):243-9. doi:10.1038/nature03308.
67. Dieude P, Guedj M, WipffJ, Ruiz B, Hachulla E, Diot E, et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum (2009) 60(8):2472-9. doi:10.1002/art.24688.
68. Ito I, Kawaguchi Y, Kawasaki A, Hasegawa M, Ohashi J, Hikami K, et al. Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis Rheum (2009) 60(6):1845-50. doi:10.1002/art.24600.
69. Dieude P, Dawidowicz K, Guedj M, Legrain Y, WipffJ, Hachulla E, et al. Phenotype-haplotype correlation of IRF5 in systemic sclerosis: role of 2 haplotypes in disease severity. J Rheumatol (2010) 37(5):987-92. doi:10.3899/jrheum.091163.
70. Dietrich N, Lienenklaus S, Weiss S, Gekara NO. Murine toll-like receptor 2 activation induces type I interferon responses from endolysosomal compartments. PLoS One (2010) 5(4):e10250. doi:10.1371/journal.pone.0010250.
71. Sato M, Taniguchi T, Tanaka N. The interferon system and interferon regulatory factor transcription factors-studies from gene knockout mice. Cytokine Growth Factor Rev (2001) 12(2-3):133-42. doi:10.1016/S1359-6101(00)00032-0.
72. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature (2005) 434(7034):772-7. doi:10.1038/nature03464.
73. Wathelet MG, Lin CH, Parekh BS, Ronco LV, Howley PM, Maniatis T. Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. Mol Cell (1998) 1(4):507-18. doi:10.1016/S1097-2765(00)80051-9.
74. Yang H, Lin CH, Ma G, BaffiMO, Wathelet MG. Interferon regulatory factor-7 synergizes with other transcription factors through multiple interactions with p300/CBP coactivators. J Biol Chem (2003) 278(18):15495-504. doi:10.1074/jbc. M212940200.
75. Yasuda K, Richez C, Maciaszek JW, Agrawal N, Akira S, Marshak-Rothstein A, et al. Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J Immunol (2007) 178(11):6876-85.
76. Sweeney SE. Targeting interferon regulatory factors to inhibit activation of the type I IFN response: implications for treatment of autoimmune disorders. Cell Immunol (2011) 271(2):342-9. doi:10.1016/j.cellimm.2011.07.014.
77. Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet (2008) 40(2):204-10. doi:10.1038/ng.81.
78. Kawasaki A, Furukawa H, Kondo Y, Ito S, Hayashi T, Kusaoi M, et al. Association of PHRF1-IRF7 region polymorphism with clinical manifestations of systemic lupus erythematosus in a Japanese population. Lupus (2012) 21(8):890-5. doi:10.1177/0961203312439333.
79. Lin LH, Ling P, Liu MF. The potential role of interferon-regulatory factor 7 among Taiwanese patients with systemic lupus erythematosus. J Rheumatol (2011) 38(9):1914-9. doi:10.3899/jrheum.101004.
80. Fu Q, Zhao J, Qian X, Wong JL, Kaufman KM, Yu CY, et al. Association of a functional IRF7 variant with systemic lupus erythematosus. Arthritis Rheum (2011) 63(3):749-54. doi:10.1002/art.30193.
81. De Oliveira DB, Almeida GM, Guedes AC, Santos FP, Bonjardim CA, Ferreira PC, et al. Basal activation of type I interferons (alpha2 and beta) and 2'5'OAS genes: insights into differential expression profiles of interferon system components in systemic sclerosis. Int J Rheumatol (2011) 2011:275617. doi:10.1155/2011/275617.
82. Zhao J, Kong HJ, Li H, Huang B, Yang M, Zhu C, et al. IRF-8/interferon (IFN) consensus sequence-binding protein is involved in toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways. J Biol Chem (2006) 281(15):10073-80. doi:10.1074/jbc. M507788200.
83. Tailor P, Tamura T, Kong HJ, Kubota T, Kubota M, Borghi P, et al. The feedback phase of type I interferon induction in dendritic cells requires interferon regulatory factor 8. Immunity (2007) 27(2):228-39. doi:10.1016/j.immuni.2007.06.009.
84. Hambleton S, Salem S, Bustamante J, Bigley V, Boisson-Dupuis S, Azevedo J, et al. IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med (2011) 365(2):127-38. doi:10.1056/NEJMoa1100066.
85. Lu R, Medina KL, Lancki DW, Singh H. IRF-4,8 orchestrate the pre-B-to-B transition in lymphocyte development. Genes Dev (2003) 17(14):1703-8. doi:10.1101/gad.1104803.
86. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A (2003) 100(21):12319-24. doi:10.1073/pnas.1635114100.
87. Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum (2009) 60(2):578-83. doi:10.1002/art.24249.
88. Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis (2010) 69(1):193-7. doi:10.1136/ard.2008.095463.
89. Sfrent-Cornateanu R, Mihai C, Balan S, Ionescu R, Moldoveanu E. The IL-6 promoter polymorphism is associated with disease activity and disability in systemic sclerosis. J Cell Mol Med (2006) 10(4):955-9. doi:10.2755/jcmm010.004.08.
90. Lee YH, Lee HS, Choi SJ, Ji JD, Song GG. The association between interleukin-6 polymorphisms and systemic lupus erythematosus: a meta-analysis. Lupus (2012) 21(1):60-7. doi:10.1177/0961203311422711.
91. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis (1993) 52(3):232-4. doi:10.1136/ard.52.3.232.
92. Kishimoto T, Hirano T. Molecular regulation of B lymphocyte response. Annu Rev Immunol (1988) 6:485-512. doi:10.1146/annurev.iy.06.040188.002413.
93. Hirano T. Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol (1992) 62(1 Pt 2):S60-5. doi:10.1016/0090-1229(92)90042-M.
94. Qiu Z, Fujimura M, Kurashima K, Nakao S, Mukaida N. Enhanced airway inflammation and decreased subepithelial fibrosis in interleukin 6-deficient mice following chronic exposure to aerosolized antigen. Clin Exp Allergy (2004) 34(8):1321-8. doi:10.1111/j.1365-2222.2004.02013.x.
95. Saito F, Tasaka S, Inoue K, Miyamoto K, Nakano Y, Ogawa Y, et al. Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am J Respir Cell Mol Biol (2008) 38(5):566-71. doi:10.1165/rcmb.2007-0299OC.
96. Hasegawa M, Sato S, Ihn H, Takehara K. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology (Oxford) (1999) 38(7):612-7. doi:10.1093/rheumatology/38.7.612.
97. De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol (2013) 40(4):435-46. doi:10.3899/jrheum.120725.
98. Laurence A, O'Shea JJ. T(H)-17 differentiation: of mice and men. Nat Immunol (2007) 8(9):903-5. doi:10.1038/ni0907-903.
99. Glimcher LH, Murphy KM. Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes Dev (2000) 14(14):1693-711.
100. Kondo K, Okada T, Matsui T, Kato S, Date K, Yoshihara M, et al. Establishment and characterization of a human B cell line from the lung tissue of a patient with scleroderma; extraordinary high level of IL-6 secretion by stimulated fibroblasts. Cytokine (2001) 13(4):220-6. doi:10.1006/cyto.2000.0822.
101. Duncan MR, Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol (1991) 97(4):686-92. doi:10.1111/1523-1747.ep12483971.
102. Liu X, Mayes MD, Tan FK, Wu M, Reveille JD, Harper BE, et al. Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis. Arthritis Rheum (2013) 65(1):226-35. doi:10.1002/art.37742.